Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain

Villa, G., Lothgren, M., Kutikova, L. et al. (7 more authors) (2017) Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39 (4). pp. 771-786. ISSN 0149-2918

Abstract

Metadata

Authors/Creators:
  • Villa, G.
  • Lothgren, M.
  • Kutikova, L.
  • Lindgren, P.
  • Gandra, S.R.
  • Fonarow, G.C.
  • Sorio, F.
  • Masana, L.
  • Bayes-Genis, A.
  • van Hout, B.
Copyright, Publisher and Additional Information: © 2017 Elsevier.
Keywords: cardiovascular disease; cost-effectiveness; evolocumab; hypercholesterolemia; LDL-C; PCSK9 inhibitors
Dates:
  • Published: April 2017
  • Published (online): 31 March 2017
  • Accepted: 22 February 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 27 Jun 2017 10:59
Last Modified: 14 Aug 2017 11:13
Published Version: https://doi.org/10.1016/j.clinthera.2017.02.011
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.clinthera.2017.02.011
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics